Bristol-Myers Squibb Company
METHODS OF AAV THERAPY
Last updated:
Abstract:
This disclosure provides methods for identifying a subject suitable for an adeno associated vims (AAV) therapy. In some embodiments, the method comprises measuring a titer of an antibody or antigen-binding portion thereof that specifically binds to an AAV ("anti-AAV antibody") in a biological sample obtained from the subject using an enzyme-linked immunosorbent assay (ELISA).
Status:
Application
Type:
Utility
Filling date:
19 Jun 2019
Issue date:
29 Apr 2021